

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 under
the Securities Exchange Act of 1934**

For the month ended February, 2013

ICON plc
(Registrant's name)

0-29714
(Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland
(Address of principal executive offices)

Brendan Brennan, CFO
South County Business Park Leopardstown, Dublin 18, Ireland.
Brendan.Brennan@iconplc.com
0011-353-1-291-2000

(Name, telephone number, email and/or facsimile number and address of Company contact person)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 **N/A**

EXHIBIT LIST

Exhibit Description

99.1 ICON plc Press Release issued February 21, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ICON plc

Date: February 21, 2013

/s/ Brendan Brennan
Brendan Brennan
Chief Financial Officer

ICON Announces Appointment of Professor William Hall to Board of Directors

DUBLIN--(BUSINESS WIRE)--February 21, 2013--**ICON plc, (NASDAQ: ICLR)**, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Professor William Hall as a non-executive director.

A renowned expert in infectious diseases and virology, Professor Hall is Chair of Medical Microbiology and Director of the Centre for Research in Infectious Diseases at University College Dublin's (UCD) School of Medicine and Medical Science. He is also a director of UCD's National Virus Reference Laboratory and is a consultant microbiologist at St. Vincent's University Hospital Dublin. Professor Hall also serves as a consultant to the Minister of Health and Children in the Republic of Ireland, providing input on a number of topics including influenza pandemic preparedness and bioterrorism.

Prior to his tenure at UCD, Professor Hall was Professor and Head of the Laboratory of Medical Virology, Senior Physician and Director of the Clinical Research Centre at the Rockefeller University in New York. He has also served as an Assistant and Associate Professor of Medicine at Cornell University.

Professor Hall is a board member of The Atlantic Philanthropies and is a co-founder of the Global Virus Network.

"We are delighted to welcome Professor Hall to the ICON Board," commented Chairman, Mr. Thomas Lynch. "His knowledge and expertise in virology and infectious diseases, coupled with his international research collaborations in these fields will complement the strengths and talents of our existing board members."

The information contained in this release is as of 21st February 2013. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON's Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.

Source: ICON plc

ICON/ICLR-F

CONTACT:

ICON plc

Investor Relations 1-888-381-7923

or

Brendan Brennan Chief Financial Officer

+ 353 -1-291-2000

or

Sam Farthing VP Investor Relations

+ 353 -1-291-2000

or

Simon Holmes EVP Investor Relations and Corporate Development

+ 353 -1-291-2000